Gene Expression Profiling for Cancer Recurrence Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tests for cancer, particularly breast cancer, are inadequate for predicting clinical outcomes and chemotherapy responses, relying heavily on estrogen receptor status and lacking in quantitative and standardized methods, leading to unnecessary exposure to toxic chemotherapy and ineffective treatment strategies.
Innovation Solution
A method involving gene expression profiling using PCR-based techniques to determine the expression levels of specific genes such as GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, and others, which correlates with clinical outcomes like Recurrence-Free Interval and Overall Survival, allowing for personalized treatment decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If gene expression profiling using PCR-based techniques is implemented, then measurement precision and prediction accuracy are improved, but device complexity and ease of operation are worsened
Solution Approach 1:
The patent uses RNA as an intermediary molecule to bridge the gap between gene expression levels and clinical outcome prediction. By measuring RNA transcripts of estrogen metabolism genes in formalin-fixed paraffin-embedded tissue, the test achieves high measurement precision without requiring complex live tissue cultures or sophisticated imaging systems. The RNA serves as a stable, measurable proxy that captures the functional state of the genes.
Solution Approach 2:
The patent replaces complex mechanical and subjective diagnostic methods (immunohistochemistry, visual assessment) with molecular biology techniques (PCR-based gene expression profiling). This substitution enables quantitative, objective measurement of gene expression levels, significantly improving prediction accuracy while the standardized protocols mitigate the complexity issue.
2Measurement precision
If RNA-based quantitative tests are used, then measurement precision is improved, but ease of operation is worsened due to RNA degradation concerns
Solution Approach 1:
The patent performs preliminary action by using formalin fixation and paraffin embedding of tissue samples before RNA extraction. This pre-treatment stabilizes the RNA by cross-linking proteins and preventing degradation, allowing quantitative RNA-based measurements to be performed on routinely archived clinical specimens without requiring special fresh-frozen tissue handling or immediate processing.
Solution Approach 2:
The patent creates a stable copy of the RNA information by using formalin-fixed paraffin-embedded tissue, which preserves RNA integrity over long periods. This allows the same tissue sample to be used for multiple analyses and stored in standard hospital archives, eliminating the need for specialized fresh tissue storage infrastructure and simplifying sample logistics.
3Ease of operation
If single analyte diagnostic tests are used, then ease of operation is improved, but measurement precision and information completeness are worsened
Solution Approach 1:
The patent merges the measurement of multiple gene expression levels (GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, CYP1B1, SULT1E1, COMT) into a single integrated diagnostic assessment. By combining these molecular markers with clinical variables through a unified statistical model, the test achieves high prediction accuracy while maintaining operational simplicity through a single laboratory assay and comprehensive report.
Solution Approach 2:
The patent creates a universal diagnostic platform that can be applied across different cancer types and clinical settings. The same gene expression profiling approach and analytical framework can predict outcomes for various cancers associated with estrogen metabolism, making the test broadly applicable and eliminating the need for multiple specialized assays.
4Productivity
If chemotherapy is administered to all patients, then productivity is improved through standardized treatment, but object-affected harmful factors increase due to toxic side effects
Solution Approach 1:
The patent applies local quality by tailoring chemotherapy treatment to individual patients based on their specific gene expression profiles and predicted recurrence risk. Rather than uniform treatment, patients are stratified into high-risk and low-risk groups, with chemotherapy selectively administered to those who will benefit most. This personalized approach maintains treatment efficiency for high-risk patients while avoiding unnecessary toxicity in low-risk patients.
Solution Approach 2:
The patent changes the decision parameter for chemotherapy administration from blanket protocols to individualized gene expression-based risk assessment. By using molecular markers to predict clinical outcome and chemotherapy response, the treatment threshold is dynamically adjusted for each patient, optimizing the balance between treatment benefit and toxicity avoidance.
Data Source
AI summary
The invention concerns genes that have been identified as being involved in estrogen metabolism, and are useful as diagnostic, prognostic and/or predictive markers in cancer. In particular, the invention concerns genes the tumor expression levels of which are useful in the diagnosis of cancers associated with estrogen metabolism, and/or in the prognosis of clinical outcome and/or prediction of drug response of such cancers.